



Universiteit
Leiden
The Netherlands

Heterologous immunity in organ transplantation

Heuvel, H. van den

Citation

Heuvel, H. van den. (2019, April 25). *Heterologous immunity in organ transplantation*. Retrieved from <https://hdl.handle.net/1887/71941>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/71941>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/71941> holds various files of this Leiden University dissertation.

Author: Heuvel, H. van den

Title: Heterologous immunity in organ transplantation

Issue Date: 2019-04-25

References

1. Hamilton D, Barker CF, Starzl TE. A history of organ transplantation : ancient legends to modern practice. Pittsburgh: University of Pittsburgh Press; 2012.
2. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. *Clin J Am Soc Nephrol* 2008;3 Suppl 2:S101-116.
3. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. *Nucleic Acids Res* 2015;43(Database issue):D423-431.
4. Burrows SR, Miles JJ. Immune parameters to consider when choosing T-cell receptors for therapy. *Frontiers in immunology* 2013;4:229.
5. Robins HS, Campregher PV, Srivastava SK, Wachter A, Turtle CJ, Kahsai O et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. *Blood* 2009;114(19):4099-4107.
6. Trautmann L, Rimbert M, Echasserieu K, Saulquin X, Neveu B, Dechanet J et al. Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. *Journal of immunology* 2005;175(9):6123-6132.
7. Argaet VP, Schmidt CW, Burrows SR, Silins SL, Kurilla MG, Doolan DL et al. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. *J Exp Med* 1994;180(6):2335-2340.
8. Benati D, Galperin M, Lambotte O, Gras S, Lim A, Mukhopadhyay M et al. Public T cell receptors confer high-avidity CD4 responses to HIV controllers. *J Clin Invest* 2016;126(6):2093-2108.
9. Stewart-Jones GB, McMichael AJ, Bell JI, Stuart DI, Jones EY. A structural basis for immunodominant human T cell receptor recognition. *Nature immunology* 2003;4(7):657-663.
10. Akram A, Inman RD. Immunodominance: a pivotal principle in host response to viral infections. *Clin Immunol* 2012;143(2):99-115.
11. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. *J Exp Med* 1994;179(4):1155-1161.
12. Lehner PJ, Wang EC, Moss PA, Williams S, Platt K, Friedman SM et al. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. *J Exp Med* 1995;181(1):79-91.
13. Moran AE, Hogquist KA. T-cell receptor affinity in thymic development. *Immunology* 2012;135(4):261-267.
14. Zhang N, Hartig H, Dzhagalov I, Draper D, He YW. The role of apoptosis in the development and function of T lymphocytes. *Cell Res* 2005;15(10):749-769.
15. Kolb HJ. Hematopoietic stem cell transplantation and cellular therapy. *HLA* 2017;89(5):267-277.

16. Moreso F, Ibernón M, Gomà M, Carrera M, Fulladosa X, Hueso M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. *Am J Transplant* 2006;6(4):747-752.
17. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. *Am J Transplant* 2018;18(2):293-307.
18. Matzinger P, Bevan MJ. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? *Cell Immunol* 1977;29(1):1-5.
19. van Besouw NM, Zuijderwijk JM, Vaessen LM, Balk AH, Maat AP, van der Meide PH et al. The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation. *Clin Exp Immunol* 2005;141(3):534-540.
20. Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, Mancini D et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. *J Clin Invest* 1996;98(5):1150-1157.
21. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. *Transplantation* 1997;64(6):795-800.
22. Molajoni ER, Cinti P, Orlandini A, Molajoni J, Tugulea S, Ho E et al. Mechanism of liver allograft rejection: the indirect recognition pathway. *Hum Immunol* 1997;53(1):57-63.
23. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. *J Immunol* 1999;162(1):352-358.
24. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. *Immunol Today* 1998;19(9):395-404.
25. Wooldridge L, Ekeruche-Makinde J, van den Berg HA, Skowera A, Miles JJ, Tan MP et al. A single autoimmune T cell receptor recognizes more than a million different peptides. *The Journal of biological chemistry* 2012;287(2):1168-1177.
26. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. *Journal of virology* 2001;75(23):11392-11400.
27. Clute SC, Naumov YN, Watkin LB, Aslan N, Sullivan JL, Thorley-Lawson DA et al. Broad cross-reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes. *Journal of immunology* 2010;185(11):6753-6764.
28. Acierno PM, Newton DA, Brown EA, Maes LA, Baatz JE, Gattoni-Celli S. Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals. *J Transl Med* 2003;1(1):3.

Chapter 9

29. Ogg GS, Kostense S, Klein MR, Jurriaans S, Hamann D, McMichael AJ et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. *J Virol* 1999;73(11):9153-9160.
30. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. *J Clin Invest* 2001;107(10):1303-1310.
31. Rowntree LC, Nguyen THO, Halim H, Purcell AW, Rossjohn J, Gras S et al. Inability To Detect Cross-Reactive Memory T Cells Challenges the Frequency of Heterologous Immunity among Common Viruses. *J Immunol* 2018;200(12):3993-4003.
32. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. *Cell* 1995;80(5):695-705.
33. Harkiolaki M, Holmes SL, Svendsen P, Gregersen JW, Jensen LT, McMahon R et al. T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. *Immunity* 2009;30(3):348-357.
34. Cho BK, Wang C, Sugawa S, Eisen HN, Chen J. Functional differences between memory and naive CD8 T cells. *Proc Natl Acad Sci U S A* 1999;96(6):2976-2981.
35. Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM et al. Heterologous immunity provides a potent barrier to transplantation tolerance. *Journal of Clinical Investigation* 2003;111(12):1887-1895.
36. Brehm MA, Daniels KA, Priyadharshini B, Thornley TB, Greiner DL, Rossini AA et al. Allografts stimulate cross-reactive virus-specific memory CD8 T cells with private specificity. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2010;10(8):1738-1748.
37. Welsh RM, Markees TG, Woda BA, Daniels KA, Brehm MA, Mordes JP et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. *Journal of virology* 2000;74(5):2210-2218.
38. Heutinck KM, Yong S, Tonneijck L, van den Heuvel H, van der Weerd NC, van der Pant KA et al. Virus-specific CD8 T-cells cross-reactive to donor-alloantigen are transiently present in the circulation of kidney transplant recipients infected with CMV and/or EBV. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2015.
39. Nguyen TH, Westall GP, Bull TE, Meehan AC, Mifsud NA, Kotsimbos TC. Cross-reactive anti-viral T cells increase prior to an episode of viral reactivation post human lung transplantation. *PLoS One* 2013;8(2):e56042.
40. Mifsud NA, Nguyen TH, Tait BD, Kotsimbos TC. Quantitative and functional diversity of cross-reactive EBV-specific CD8+ T cells in a longitudinal study cohort of lung transplant recipients. *Transplantation* 2010;90(12):1439-1449.

41. Rowntree LC, Nguyen TH, Gras S, Kotsimbos TC, Mifsud NA. Deciphering the clinical relevance of allo-human leukocyte antigen cross-reactivity in mediating alloimmunity following transplantation. *Curr Opin Organ Transplant* 2016;21(1):29-39.
42. Morice A, Charreau B, Neveu B, Brouard S, Souillou JP, Bonneville M et al. Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules. *PLoS One* 2010;5(8):e12120.
43. Amir AL, D'Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R et al. Allo-HLA reactivity of virus-specific memory T cells is common. *Blood* 2010;115(15):3146-3157.
44. Macdonald WA, Chen Z, Gras S, Archbold JK, Tynan FE, Clements CS et al. T cell allorecognition via molecular mimicry. *Immunity* 2009;31(6):897-908.
45. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *The New England journal of medicine* 2007;357(25):2562-2575.
46. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. *Clin J Am Soc Nephrol* 2009;4(2):481-508.
47. Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC, Krishnan AV. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. *Am J Transplant* 2013;13(9):2426-2432.
48. Kesiraju S, Paritala P, Rao Ch UM, Sahariah S. New onset of diabetes after transplantation - an overview of epidemiology, mechanism of development and diagnosis. *Transpl Immunol* 2014;30(1):52-58.
49. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2012;27(2):850-857.
50. Mengel M, Marwedel M, Radermacher J, Eden G, Schwarz A, Haller H et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. *Nephrol Dial Transplant* 2003;18(6):1190-1196.
51. Badell IR, Kitchens WH, Wagener ME, Lukacher AE, Larsen CP, Ford ML. Pathogen Stimulation History Impacts Donor-Specific CD8 T Cell Susceptibility to Costimulation/Integrin Blockade-Based Therapy. *Am J Transplant* 2015.
52. de Graav GN, Hesselink DA, Dieterich M, Kraaijeveld R, Douben H, de Klein A et al. An Acute Cellular Rejection With Detrimental Outcome Occurring Under Belatacept-Based Immunosuppressive Therapy: An Immunological Analysis. *Transplantation* 2015.
53. Xu H, Perez SD, Cheeseman J, Mehta AK, Kirk AD. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. *Am J Transplant* 2014;14(2):319-332.
54. Yin Y, Mariuzza RA. The multiple mechanisms of T cell receptor cross-reactivity. *Immunity* 2009;31(6):849-851.

Chapter 9

55. Reiser JB, Darnault C, Gregoire C, Mosser T, Mazza G, Kearney A et al. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. *Nat Immunol* 2003;4(3):241-247.
56. Jones LL, Colf LA, Stone JD, Garcia KC, Kranz DM. Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation. *J Immunol* 2008;181(9):6255-6264.
57. Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR et al. Naive and memory T cells induce different types of graft-versus-host disease. *Journal of immunology* 2007;179(10):6547-6554.
58. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2005;5(3):582-594.
59. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. *The Cochrane database of systematic reviews* 2014;11:CD010699.
60. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. *J Am Soc Nephrol* 2003;14(9):2402-2410.
61. Nadazdin O, Boskovic S, Murakami T, Tocco G, Smith RN, Colvin RB et al. Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. *Science translational medicine* 2011;3(86):86ra51.
62. Sivaganesh S, Harper SJ, Conlon TM, Callaghan CJ, Saeb-Parsy K, Negus MC et al. Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells. *Journal of immunology* 2013;190(11):5829-5838.
63. Ishii D, Rosenblum JM, Nozaki T, Schenk AD, Setoguchi K, Su CA et al. Novel CD8 T cell alloreactivities in CCR5-deficient recipients of class II MHC disparate kidney grafts. *Journal of immunology* 2014;193(7):3816-3824.
64. Mai HL, Boeffard F, Longis J, Danger R, Martinet B, Haspot F et al. IL-7 receptor blockade following T cell depletion promotes long-term allograft survival. *J Clin Invest* 2014;124(4):1723-1733.
65. Lee S, Yamada Y, Tonsho M, Boskovic S, Nadazdin O, Schoenfeld D et al. Alefacept promotes immunosuppression-free renal allograft survival in nonhuman primates via depletion of recipient memory T cells. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2013;13(12):3223-3229.
66. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. *The Journal of experimental medicine* 2000;192(4):549-556.
67. Mbitikon-Kobo FM, Vocanson M, Michallet MC, Tomkowiak M, Cottalorda A, Angelov GS et al. Characterization of a CD44/CD122^{int} memory CD8 T cell subset generated under sterile inflammatory conditions. *Journal of immunology* 2009;182(6):3846-3854.

68. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2008;8(8):1652-1661.
69. Su CA, Iida S, Abe T, Fairchild RL. Endogenous memory CD8 T cells directly mediate cardiac allograft rejection. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2014;14(3):568-579.
70. Cottalorda A, Mercier BC, Mbitikon-Kobo FM, Arpin C, Teoh DY, McMichael A et al. TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-gamma secretion in the absence of Ag. *European journal of immunology* 2009;39(10):2673-2681.
71. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. *Nat Med* 1999;5(11):1249-1255.
72. Krupnick AS, Lin X, Li W, Higashikubo R, Zinselmeyer BH, Hartzler H et al. Central memory CD8+ T lymphocytes mediate lung allograft acceptance. *J Clin Invest* 2014;124(3):1130-1143.
73. Lentsch AB, Ward PA. Regulation of experimental lung inflammation. *Respiration physiology* 2001;128(1):17-22.
74. Kant CD, Akiyama Y, Tanaka K, Shea S, Connolly SE, Germana S et al. Primary vascularization of allografts governs their immunogenicity and susceptibility to tolerogenesis. *Journal of immunology* 2013;191(4):1948-1956.
75. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). *Am J Transplant* 2010;10(3):535-546.
76. Lo DJ, Anderson DJ, Weaver TA, Leopardi F, Song M, Farris AB et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2013;13(2):320-328.
77. Kirk AD, Guasch A, Xu H, Cheeseman J, Mead SI, Ghali A et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2014;14(5):1142-1151.
78. Demmers MW, Baan CC, Janssen M, Litjens NH, Ijzermans JN, Betjes MG et al. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. *Transplantation* 2014;97(1):47-55.
79. Betjes MG, Huisman M, Weimar W, Litjens NH. Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. *Kidney international* 2008;74(6):760-767.

80. van Leeuwen EM, Remmerswaal EB, Vossen MT, Rowshani AT, Wertheim-van Dillen PM, van Lier RA et al. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. *J Immunol* 2004;173(3):1834-1841.
81. Jane-Wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kappaB signaling in endothelial cells. *Circulation* 2013;128(23):2504-2516.
82. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. *Immunity* 2008;28(3):425-435.
83. van der Touw W, Cravedi P, Kwan WH, Paz-Artal E, Merad M, Heeger PS. Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. *Journal of immunology* 2013;190(12):5921-5925.
84. Donckier V, Craciun L, Miqueu P, Troisi RI, Lucidi V, Rogiers X et al. Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin. *Transplantation* 2013;96(3):306-315.
85. Roux A, Mourin G, Fastenackels S, Almeida JR, Iglesias MC, Boyd A et al. CMV driven CD8(+) T-cell activation is associated with acute rejection in lung transplantation. *Clinical immunology* 2013;148(1):16-26.
86. Nguyen TH, Rowntree LC, Pellicci DG, Bird NL, Handel A, Kjer-Nielsen L et al. Recognition of Distinct Cross-Reactive Virus-Specific CD8+ T Cells Reveals a Unique TCR Signature in a Clinical Setting. *Journal of immunology* 2014;192(11):5039-5049.
87. D'Orsogna LJ, Roelen DL, van der Meer-Prins EM, van der Pol P, Franke-van Dijk ME, Eikmans M et al. Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells. *Transplantation* 2011;91(5):494-500.
88. Andreani M, Testi M, Lucarelli G. Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance. *Tissue antigens* 2014;83(3):137-146.
89. Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A et al. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. *PloS one* 2014;9(11):e113764.
90. Westerhuis G, de Witte M, Schumacher TN, Toes RE, Fibbe WE. Barriers to chimerism after major histocompatibility complex-mismatched stem cell transplantation: a potential role for heterologous immunity. *Exp Hematol* 2014;42(9):753-760.
91. Kontoyiannis DP, Lewis RE, Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* 2009;15(1 Suppl):128-133.
92. Cherel M, Choufi B, Trauet J, Cracco P, Dessaint JP, Yakoub-Agha I et al. Naive subset develops the most important alloreactive response among human CD4+ T lymphocytes in human leukocyte antigen-identical related setting. *Eur J Haematol* 2014;92(6):491-496.

93. Distler E, Bloetz A, Albrecht J, Asdufan S, Hohberger A, Frey M et al. Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells. *Haematologica* 2011;96(7):1024-1032.
94. Teschner D, Distler E, Wehler D, Frey M, Marandiu D, Langeveld K et al. Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis. *Bone marrow transplantation* 2014;49(1):138-144.
95. Juvet SC, Whatcott AG, Bushell AR, Wood KJ. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2014;14(4):750-763.
96. Rutten CE, van Luxemburg-Heijs SA, Griffioen M, Marijt EW, Jedema I, Heemskerk MH et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. *Leukemia* 2008;22(7):1387-1394.
97. Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB et al. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. *Blood* 2013;122(11):1963-1973.
98. Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. *The lancet oncology* 2012;13(4):366-374.
99. Lauterbach N, Crivello P, Wieten L, Zito L, Groeneweg M, Voorter CE et al. Allorecognition of HLA-DP by CD4+ T cells is affected by polymorphism in its alpha chain. *Molecular immunology* 2014;59(1):19-29.
100. Crivello P, Zito L, Sizzano F, Zino E, Maiers M, Mulder A et al. The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* 2014.
101. Fleischhauer K, Fernandez-Vina MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA et al. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. *Bone marrow transplantation* 2014;49(9):1176-1183.
102. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. *Blood* 2013;121(26):5113-5123.
103. Karuthu S, Blumberg EA. Common infections in kidney transplant recipients. *Clinical journal of the American Society of Nephrology : CJASN* 2012;7(12):2058-2070.
104. van Aalderen MC, Heutink KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. *The Netherlands journal of medicine* 2012;70(4):172-183.

105. Shalhoub S, Husain S. Community-acquired respiratory viral infections in lung transplant recipients. *Current opinion in infectious diseases* 2013;26(4):302-308.
106. van de Berg PJ, Heutinck KM, Raabe R, Minnee RC, Young SL, van Donselaar-van der Pant KA et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. *The Journal of infectious diseases* 2010;202(5):690-699.
107. Williams MA, Onami TM, Adams AB, Durham MM, Pearson TC, Ahmed R et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. *Journal of immunology* 2002;169(10):5387-5391.
108. Felix NJ, Donermeyer DL, Horvath S, Walters JJ, Gross ML, Suri A et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. *Nature immunology* 2007;8(4):388-397.
109. Macedo C, Walters JT, Orkis EA, Isse K, Elinoff BD, Fedorek SP et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. *Transplantation* 2012;93(8):813-821.
110. Jones DL, Sacks SH, Wong W. Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants. *Transplantation* 2006;82(10):1352-1361.
111. Suthanthiran M, Strom TB. Renal transplantation. *The New England journal of medicine* 1994;331(6):365-376.
112. Brook MO, Wood KJ, Jones ND. The impact of memory T cells on rejection and the induction of tolerance. *Transplantation* 2006;82(1):1-9.
113. Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2010;10(5):1126-1134.
114. Ingulli E. Mechanism of cellular rejection in transplantation. *Pediatric nephrology* 2010;25(1):61-74.
115. Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. *Journal of immunology* 1999;163(4):2267-2275.
116. Poggio ED, Augustine JJ. Alloreactive T cells and 'the persistence of memory'. *Kidney international* 2013;84(6):1074-1076.
117. Zoet YM, Eijsink C, Kardol MJ, Franke-van Dijk ME, Wilson GL, de Paus R et al. The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. *Human immunology* 2005;66(5):519-525.
118. D'Orsogna LJ, van der Meer-Prins EM, Zoet YM, Roelen DL, Doxiadis II, Claas FH. Detection of allo-HLA cross-reactivity by virus-specific memory T-cell clones using single HLA-transfected K562 cells. *Methods in molecular biology* 2012;882:339-349.
119. Wei S, Charnley P, Robinson MA, Concannon P. The extent of the human germline T-cell receptor V beta gene segment repertoire. *Immunogenetics* 1994;40(1):27-36.

120. Ticchioni M, Ausssel C, Breittmayer JP, Manie S, Pelassy C, Bernard A. Suppressive effect of T cell proliferation via the CD29 molecule. The CD29 mAb 1 "K20" decreases diacylglycerol and phosphatidic acid levels in activated T cells. *Journal of immunology* 1993;151(1):119-127.
121. D'Orsogna LJ, Amir AL, Zoet YM, van der Meer-Prins PM, van der Slik AR, Kester MG et al. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire. *Tissue antigens* 2009;74(4):290-297.
122. Sheehy MJ, Sondel PM, Bach ML, Wank R, Bach FH. HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes. *Science* 1975;188(4195):1308-1310.
123. Hayry P, Andersson LC. Sequential responses of mouse spleen T cells in mixed lymphocyte culture-induced cytotoxicity. *The Journal of experimental medicine* 1975;141(2):508-512.
124. Litjens NH, de Wit EA, Baan CC, Betjes MG. Activation-induced CD137 is a fast assay for identification and multi-parameter flow cytometric analysis of alloreactive T cells. *Clinical and experimental immunology* 2013;174(1):179-191.
125. Wolf M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. *Blood* 2007;110(1):201-210.
126. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. *Immunology* 1968;14(2):181-196.
127. Gamadia LE, Remmerswaal EB, Surachno S, Lardy NM, Wertheim-van Dillen PM, van Lier RA et al. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. *Transplantation* 2004;77(12):1879-1885.
128. Rist M, Smith C, Bell MJ, Burrows SR, Khanna R. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition. *Blood* 2009;114(11):2244-2253.
129. Amir AL, van der Steen DM, Hagedoorn RS, Kester MG, van Bergen CA, Drijfhout JW et al. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. *Blood* 2011;118(26):6733-6742.
130. Heath WR, Sherman LA. Cell-type-specific recognition of allogeneic cells by alloreactive cytotoxic T cells: a consequence of peptide-dependent allorecognition. *European journal of immunology* 1991;21(1):153-159.
131. Kummer M, Lev A, Reiter Y, Biedermann BC. Vascular endothelial cells have impaired capacity to present immunodominant, antigenic peptides: a mechanism of cell type-specific immune escape. *Journal of immunology* 2005;174(4):1947-1953.
132. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. *Journal of immunological methods* 2002;259(1-2):95-110.

133. Colf LA, Bankovich AJ, Hanick NA, Bowerman NA, Jones LL, Kranz DM et al. How a single T cell receptor recognizes both self and foreign MHC. *Cell* 2007;129(1):135-146.
134. Rossjohn J, McCluskey J. How a home-grown T cell receptor interacts with a foreign landscape. *Cell* 2007;129(1):19-20.
135. Archbold JK, Macdonald WA, Miles JJ, Brennan RM, Kjer-Nielsen L, McCluskey J et al. Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is the result of highly focused, peptide-dependent structural mimicry. *The Journal of biological chemistry* 2006;281(45):34324-34332.
136. Heemskerck MB, Cornelissen JJ, Roelen DL, van Rood JJ, Claas FH, Doxiadis, II et al. Highly diverged MHC class I mismatches are acceptable for haematopoietic stem cell transplantation. *Bone marrow transplantation* 2007;40(3):193-200.
137. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K et al. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. *PLoS One* 2012;7(2):e31465.
138. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. *Curr Opin Infect Dis* 2005;18(4):342-345.
139. de Graav GN, Baan CC, Clahsen-van Groningen MC, Kraaijeveld R, Dieterich M, Verschoor W et al. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. *Transplantation* 2017;101(10):2571-2581.
140. van den Heuvel H, Heutinck KM, van der Meer-Prins EMW, Yong SL, van Miert PPMC, Anholts JDH et al. Allo-HLA Cross-Reactivities of Cytomegalovirus-, Influenza-, and Varicella Zoster Virus-Specific Memory T Cells Are Shared by Different Healthy Individuals. *Am J Transplant* 2017;17(8):2033-2044.
141. Gras S, Kjer-Nielsen L, Chen Z, Rossjohn J, McCluskey J. The structural bases of direct T-cell allorecognition: implications for T-cell-mediated transplant rejection. *Immunol Cell Biol* 2011;89(3):388-395.
142. Heutinck KM, Yong SL, Tonneijck L, van den Heuvel H, van der Weerd NC, van der Pant KA et al. Virus-Specific CD8(+) T Cells Cross-Reactive to Donor-Alloantigen Are Transiently Present in the Circulation of Kidney Transplant Recipients Infected With CMV and/or EBV. *Am J Transplant* 2016;16(5):1480-1491.
143. D'Orsogna LJ, van den Heuvel H, van der Meer-Prins EM, Roelen DL, Doxiadis, II, Claas FH. Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules. *J Immunol* 2012;189(10):4825-4831.
144. van den Heuvel H, Heutinck KM, van der Meer-Prins EMW, Franke-van Dijk MEI, van Miert PPMC, Zhang X et al. The avidity of cross-reactive virus-specific T cells for their viral and allogeneic epitopes is variable and depends on epitope expression. *Hum Immunol* 2018;79(1):39-50.
145. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. *Blood* 1994;83(7):1971-1979.
146. Biron KK. Antiviral drugs for cytomegalovirus diseases. *Antiviral Res* 2006;71(2-3):154-163.

147. Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. *Virology* 2015;479-480:180-193.
148. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. *J Exp Med* 1997;186(9):1407-1418.
149. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol* 2004;22:745-763.
150. McMichael AJ. Triple bypass: complicated paths to HIV escape. *J Exp Med* 2007;204(12):2785-2788.
151. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med* 2010;362(5):402-415.
152. Einsele H. T-cell therapy for viral and fungal infections. In.: *Blood*, 2005.
153. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2007;13(6):707-714.
154. Peggs KS, Mackinnon S. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. *Hum Immunol* 2004;65(5):550-557.
155. Brander C, Corradin G, Hasler T, Pichler WJ. Peptide immunization in humans: a combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL). *Clin Exp Immunol* 1996;105(1):18-25.
156. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. *J Exp Med* 1991;174(5):969-974.
157. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. *Nat Immunol* 2002;3(7):627-634.
158. Allam A, Conze DB, Giardino Torchia ML, Munitic I, Yagita H, Sowell RT et al. The CD8+ memory T-cell state of readiness is actively maintained and reversible. *Blood* 2009;114(10):2121-2130.
159. Gaston JS, Rickinson AB, Epstein MA. Cross-reactivity of self-HLA-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo-HLA determinants. *J Exp Med* 1983;158(6):1804-1821.
160. Landais E, Morice A, Long HM, Haigh TA, Charreau B, Bonneville M et al. EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses. *J Immunol* 2006;177(3):1427-1433.
161. D'Orsogna LJ, Roelen DL, Doxiadis, II, Claas FH. Alloreactivity from human viral specific memory T-cells. *Transplant immunology* 2010;23(4):149-155.
162. Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. *Biol Blood Marrow Transplant* 2004;10(7):433-447.
163. Yi-qun Z, Joost van Neerven RJ, Kasran A, de Boer M, Ceuppens JL. Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. *Int Immunol* 1996;8(1):37-44.

Chapter 9

164. Ploegh HL. Viral strategies of immune evasion. *Science* 1998;280(5361):248-253.
165. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. *Annu Rev Immunol* 2000;18:861-926.
166. Pinto AK, Hill AB. Viral interference with antigen presentation to CD8+ T cells: lessons from cytomegalovirus. *Viral Immunol* 2005;18(3):434-444.
167. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. *J Immunol* 1993;151(9):4455-4464.
168. Wiertz EJ, Jones TR, Sun L, Bogoy M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. *Cell* 1996;84(5):769-779.
169. Pinto AK, Munks MW, Koszinowski UH, Hill AB. Coordinated function of murine cytomegalovirus genes completely inhibits CTL lysis. *J Immunol* 2006;177(5):3225-3234.
170. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. *Cell* 1994;77(4):525-535.
171. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. *Proc Natl Acad Sci U S A* 1997;94(23):12616-12621.
172. Hussain A, Wesley C, Khalid M, Chaudhry A, Jameel S. Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. *J Virol* 2008;82(2):893-902.
173. Kawashima Y, Pfafferoth K, Frater J, Matthews P, Payne R, Addo M et al. Adaptation of HIV-1 to human leukocyte antigen class I. *Nature* 2009;458(7238):641-645.
174. Friedrich TC, Piaskowski SM, León EJ, Furlott JR, Maness NJ, Weisgrau KL et al. High viremia is associated with high levels of in vivo major histocompatibility complex class I Downregulation in rhesus macaques infected with simian immunodeficiency virus SIVmac239. *J Virol* 2010;84(10):5443-5447.
175. Wiertz E, Hill A, Tortorella D, Ploegh H. Cytomegaloviruses use multiple mechanisms to elude the host immune response. *Immunol Lett* 1997;57(1-3):213-216.
176. Stevenson PG, May JS, Smith XG, Marques S, Adler H, Koszinowski UH et al. K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. *Nat Immunol* 2002;3(8):733-740.
177. Mintern JD, Klemm EJ, Wagner M, Paquet ME, Napier MD, Kim YM et al. Viral interference with B7-1 costimulation: a new role for murine cytomegalovirus fc receptor-1. *J Immunol* 2006;177(12):8422-8431.
178. Doom CM, Hill AB. MHC class I immune evasion in MCMV infection. *Med Microbiol Immunol* 2008;197(2):191-204.
179. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. *Science* 2010;328(5974):102-106.

180. Steffens HP, Kurz S, Holtappels R, Reddehase MJ. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. *J Virol* 1998;72(3):1797-1804.
181. Byrne JA, Butler JL, Cooper MD. Differential activation requirements for virgin and memory T cells. *J Immunol* 1988;141(10):3249-3257.
182. Risdon G, Gaddy J, Horie M, Broxmeyer HE. Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells. *Proc Natl Acad Sci U S A* 1995;92(6):2413-2417.
183. Slavcev A, Stríz I, Ivasková E, Breur-Vriesendorp BS. Alloresponses of cord blood cells in primary mixed lymphocyte cultures. *Hum Immunol* 2002;63(3):155-163.
184. Haskova Z, Sproule TJ, Roopenian DC, Ksander AB. An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection. *Transplantation* 2003;75(8):1368-1374.
185. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. *Journal of immunology* 2005;174(5):3051-3058.
186. Venturi V, Price DA, Douek DC, Davenport MP. The molecular basis for public T-cell responses? *Nature reviews Immunology* 2008;8(3):231-238.
187. Brennan RM, Miles JJ, Silins SL, Bell MJ, Burrows JM, Burrows SR. Predictable alphabeta T-cell receptor selection toward an HLA-B*3501-restricted human cytomegalovirus epitope. *Journal of virology* 2007;81(13):7269-7273.
188. Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM. Private specificities of CD8 T cell responses control patterns of heterologous immunity. *The Journal of experimental medicine* 2005;201(4):523-533.
189. Elkington R, Khanna R. Cross-recognition of human alloantigen by cytomegalovirus glycoprotein-specific CD4+ cytotoxic T lymphocytes: implications for graft-versus-host disease. *Blood* 2005;105(3):1362-1364.
190. Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, Miles JJ et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. *Nat Immunol* 2005;6(11):1114-1122.
191. Koelle DM, Chen HB, McClurkan CM, Petersdorf EW. Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. *Blood* 2002;99(10):3844-3847.
192. Burrows SR, Silins SL, Khanna R, Burrows JM, Rischmueller M, McCluskey J et al. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. *Eur J Immunol* 1997;27(7):1726-1736.
193. D'Orsogna LJ, van Besouw NM, van der Meer-Prins EM, van der Pol P, Franke-van Dijk M, Zoet YM et al. Vaccine-induced allo-HLA-reactive memory T cells in a kidney transplantation candidate. *Transplantation* 2011;91(6):645-651.
194. Kristensen T. Human Histocompatibility Testing by T-Cell-Mediated Lympholysis - a European Standard Cml Technique. *Tissue antigens* 1980;16(5):335-367.

195. Moss PA, Moots RJ, Rosenberg WM, Rowland-Jones SJ, Bodmer HC, McMichael AJ et al. Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. *Proceedings of the National Academy of Sciences of the United States of America* 1991;88(20):8987-8990.
196. van der Heiden PL, de Boer R, van der Steen DM, Kester MG, van der Hoorn MW, Haarman WM et al. Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation. *Journal of virology* 2009;83(14):7361-7364.
197. Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, Argat VP. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. *The Journal of experimental medicine* 1995;182(6):1703-1715.
198. Gras S, Burrows SR, Kjer-Nielsen L, Clements CS, Liu YC, Sullivan LC et al. The shaping of T cell receptor recognition by self-tolerance. *Immunity* 2009;30(2):193-203.
199. Burrows SR, Silins SL, Cross SM, Peh CA, Rischmueller M, Burrows JM et al. Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire. *European journal of immunology* 1997;27(1):178-182.
200. Ooba T, Hayashi H, Karaki S, Tanabe M, Kano K, Takiguchi M. The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two genetic mechanisms. *Immunogenetics* 1989;30(2):76-80.
201. Cano P, Fan B, Stass S. A geometric study of the amino acid sequence of class I HLA molecules. *Immunogenetics* 1998;48(5):324-334.
202. Ishizuka J, Stewart-Jones GB, van der Merwe A, Bell JI, McMichael AJ, Jones EY. The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain. *Immunity* 2008;28(2):171-182.
203. Baker BM, Turner RV, Gagnon SJ, Wiley DC, Biddison WE. Identification of a crucial energetic footprint on the alpha1 helix of human histocompatibility leukocyte antigen (HLA)-A2 that provides functional interactions for recognition by tax peptide/HLA-A2-specific T cell receptors. *The Journal of experimental medicine* 2001;193(5):551-562.
204. Adams JJ, Narayanan S, Liu B, Birnbaum ME, Kruse AC, Bowerman NA et al. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. *Immunity* 2011;35(5):681-693.
205. Ely LK, Green KJ, Beddoe T, Clements CS, Miles JJ, Bottomley SP et al. Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: implications for allograft rejection. *J Immunol* 2005;174(9):5593-5601.
206. Ford ML, Kirk AD, Larsen CP. Donor-reactive T-cell stimulation history and precursor frequency: barriers to tolerance induction. *Transplantation* 2009;87(9 Suppl):S69-74.
207. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X et al. Homeostatic proliferation is a barrier to transplantation tolerance. *Nature medicine* 2004;10(1):87-92.

208. Klarenbeek PL, Remmerswaal EB, ten Berge IJ, Doorenspleet ME, van Schaik BD, Esveldt RE et al. Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years. *PLoS pathogens* 2012;8(9):e1002889.
209. Havenith SH, Remmerswaal EB, Bemelman FJ, Yong SL, van Donselaar-van der Pant KA, van Lier RA et al. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus. *Clinical and experimental immunology* 2012;169(3):292-301.
210. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. *Science* 1999;286(5441):958-961.
211. van Emmerik NE, Vaessen LM, Balk AH, Bos E, Claas FH, Weimar W. Progressive accumulation of CTL with high avidity for donor antigens during the development of acute cardiac rejection. *Transplantation* 1996;62(4):529-536.
212. van Emmerik NE, Vaessen LM, Knoop CJ, Daane CR, Balk AH, Mochtar B et al. Kinetics of circulating cytotoxic T lymphocyte precursors that have a high avidity for donor antigens: correlation with the rejection status of the human cardiac allograft. *Transpl Immunol* 1998;6(3):153-160.
213. Wulfing C, Rabinowitz JD, Beeson C, Sjaastad MD, McConnell HM, Davis MM. Kinetics and extent of T cell activation as measured with the calcium signal. *The Journal of experimental medicine* 1997;185(10):1815-1825.
214. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. *Journal of immunology* 2011;186(9):5039-5045.
215. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. *Immunology* 2009;126(2):165-176.
216. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. *Science* 1995;267(5197):515-518.
217. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. *Cell* 1994;79(5):913-922.
218. Nel AE, Slaughter N. T-cell activation through the antigen receptor. Part 2: role of signaling cascades in T-cell differentiation, anergy, immune senescence, and development of immunotherapy. *J Allergy Clin Immunol* 2002;109(6):901-915.
219. Auphan-Anezin N, Mazza C, Guimezanes A, Barrett-Wilt GA, Montero-Julian F, Roussel A et al. Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes. *Eur J Immunol* 2006;36(7):1856-1866.
220. Jenkins MR, Tsun A, Stinchcombe JC, Griffiths GM. The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. *Immunity* 2009;31(4):621-631.
221. Lyons DS, Lieberman SA, Hampl J, Boniface JJ, Chien Y, Berg LJ et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. *Immunity* 1996;5(1):53-61.
222. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. *Immunity* 1999;10(4):485-492.

Chapter 9

223. Margulies DH, Plaksin D, Khilko SN, Jelonek MT. Studying interactions involving the T-cell antigen receptor by surface plasmon resonance. *Current opinion in immunology* 1996;8(2):262-270.
224. Huppa JB, Axmann M, Mortelmaier MA, Lillemeier BF, Newell EW, Brameshuber M et al. TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. *Nature* 2010;463(7283):963-967.
225. Chesla SE, Selvaraj P, Zhu C. Measuring two-dimensional receptor-ligand binding kinetics by micropipette. *Biophysical journal* 1998;75(3):1553-1572.
226. van den Heuvel H, Heutinck KM, van der Meer-Prins EP, Yong SL, Claas FH, Ten Berge IJ. Detection of Virus-Specific CD8+ T Cells With Cross-Reactivity Against Alloantigens: Potency and Flaws of Present Experimental Methods. *Transplant Direct* 2015;1(10):e40.
227. Roelen D, Datema G, van Bree S, Zhang L, van Rood J, Claas F. Evidence that antibody formation against a certain HLA alloantigen is associated not with a quantitative but with a qualitative change in the cytotoxic T cells recognizing the same antigen. *Transplantation* 1992;53(4):899-903.
228. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. *Immunity* 2003;18(2):255-264.
229. van den Heuvel H, Heutinck KM, van der Meer-Prins EM, Yong SL, van Miert PP, Anholts JD et al. Allo-HLA Cross-Reactivities of CMV-, FLU- and VZV-Specific Memory T Cells Are Shared by Different Individuals. *Am J Transplant* 2017.
230. Anikeeva N, Gakamsky D, Scholler J, Sykulev Y. Evidence that the density of self peptide-MHC ligands regulates T-cell receptor signaling. *PloS one* 2012;7(8):e41466.
231. Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G et al. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. *Proceedings of the National Academy of Sciences of the United States of America* 2012;109(3):881-886.
232. Henrickson SE, Mempel TR, Mazo IB, Liu B, Artyomov MN, Zheng H et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. *Nature immunology* 2008;9(3):282-291.
233. Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H et al. The human leukocyte antigen-presented ligandome of B lymphocytes. *Molecular & cellular proteomics : MCP* 2013;12(7):1829-1843.
234. Wooldridge L, van den Berg HA, Glick M, Gostick E, Laugel B, Hutchinson SL et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. *J Biol Chem* 2005;280(30):27491-27501.
235. Purbhoo MA, Boulter JM, Price DA, Vuidepot AL, Hourigan CS, Dunbar PR et al. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. *J Biol Chem* 2001;276(35):32786-32792.
236. van den Berg HA, Wooldridge L, Laugel B, Sewell AK. Coreceptor CD8-driven modulation of T cell antigen receptor specificity. *J Theor Biol* 2007;249(2):395-408.

237. Kerry SE, Buslepp J, Cramer LA, Maile R, Hensley LL, Nielsen AI et al. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. *J Immunol* 2003;171(9):4493-4503.
238. Wooldridge L, Laugel B, Ekeruche J, Clement M, van den Berg HA, Price DA et al. CD8 controls T cell cross-reactivity. *J Immunol* 2010;185(8):4625-4632.
239. Fahmy TM, Bieler JG, Edidin M, Schneck JP. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. *Immunity* 2001;14(2):135-143.
240. Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, Evavold BD et al. The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. *Nature* 2010;464(7290):932-936.
241. D'Orsogna L, van den Heuvel H, van Kooten C, Heidt S, Claas FHJ. Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. *Immunogenetics* 2017;69(8-9):631-641.
242. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? *Lancet Infect Dis* 2002;2(9):539-549.
243. Weikert BC, Blumberg EA. Viral infection after renal transplantation: surveillance and management. *Clin J Am Soc Nephrol* 2008;3 Suppl 2:S76-86.
244. Babel N, Schwarzmann F, Prang N, Jaeger M, Wolf H, Kern F et al. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. *Transplantation* 2001;72(4):736-739.
245. Walker JD, Maier CL, Pober JS. Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes. *J Immunol* 2009;182(3):1548-1559.
246. Reischig T. Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies. *Expert Rev Anti Infect Ther* 2010;8(8):903-910.
247. Krummey SM, Ford ML. Heterogeneity within T Cell Memory: Implications for Transplant Tolerance. *Front Immunol* 2012;3:36.
248. Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. *Cochrane Database Syst Rev* 2017;7:CD006750.
249. O'Connell PJ, Kuypers DR, Mannon RB, Abecassis M, Chadban SJ, Gill JS et al. Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. *Transplantation* 2017;101(7):1527-1534.
250. Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. *J Immunol* 2002;169(7):3686-3693.
251. Hall CE, Koparde VN, Jameson-Lee M, Elnasseh AG, Scalora AF, Kobulnicky DJ et al. Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivity. *PLoS One* 2017;12(8):e0178763.

Chapter 9

252. van Besouw NM, van der Mast BJ, de Kuiper P, Smak Gregoor PJ, Vaessen LM, IJzermans JN et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. *Transplantation* 2000;70(1):136-143.
253. Roemhild A, Reinke P. Virus-specific T-cell therapy in solid organ transplantation. *Transpl Int* 2016;29(5):515-526.
254. Hutchinson SL, Wooldridge L, Tafuro S, Laugel B, Glick M, Boulter JM et al. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. *J Biol Chem* 2003;278(27):24285-24293.
255. Blok R, Margulies DH, Pease L, Ribaldo RK, Schneck J, McCluskey J. CD8 expression alters the fine specificity of an alloreactive MHC class I-specific T hybridoma. *Int Immunol* 1992;4(4):455-466.
256. Wang Y, Singh NK, Spear TT, Hellman LM, Piepenbrink KH, McMahan RH et al. How an alloreactive T-cell receptor achieves peptide and MHC specificity. *Proc Natl Acad Sci U S A* 2017;114(24):E4792-E4801.
257. Gao GF, Willcox BE, Wyer JR, Boulter JM, O'Callaghan CA, Maenaka K et al. Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha. *The Journal of biological chemistry* 2000;275(20):15232-15238.
258. Buslepp J, Wang H, Biddison WE, Appella E, Collins EJ. A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection. *Immunity* 2003;19(4):595-606.
259. Martinez RJ, Evavold BD. Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response. *Front Immunol* 2015;6:468.
260. Krummey SM, Martinez RJ, Andargachew R, Liu D, Wagener M, Kohlmeier JE et al. Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity. *J Immunol* 2016;196(6):2838-2846.
261. Almeida CA, van Miert P, O'Driscoll K, Zoet YM, Chopra A, Watson M et al. Stimulation of HIV-specific T cell clonotypes using allogeneic HLA. *Cell Immunol* 2017;316:32-40.
262. Crawford F, Jordan KR, Stadinski B, Wang Y, Huseby E, Marrack P et al. Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. *Immunol Rev* 2006;210:156-170.
263. Ekeruche-Makinde J, Miles JJ, van den Berg HA, Skowera A, Cole DK, Dolton G et al. Peptide length determines the outcome of TCR/peptide-MHCI engagement. *Blood* 2013;121(7):1112-1123.
264. Szomolay B, Liu J, Brown PE, Miles JJ, Clement M, Llewellyn-Lacey S et al. Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors. *Immunol Cell Biol* 2016;94(6):573-582.

Publicaties

Van den Heuvel H, van der Meer-Prins EMW, van Miert PPMC, Zhang X, Anholts JDH, Claas FHJ. Infection with a virus generates a polyclonal immune response with broad alloreactive potential. *Hum Immunol*. 2019;80(2):97-102

Van der Zwan A, van der Meer-Prins EMW, van Miert PPMC, **van den Heuvel H**, Anholts JDH, Roelen DL, Claas FHJ, Heidt S. Cross-reactivity of virus-specific CD8⁺ T cells against allogeneic HLA-C: possible implications for pregnancy outcome. *Front Immunol*. 2018 Dec 6;9:2880

Van den Heuvel H, Heutinck KM, van der Meer-Prins EMW, Franke-van Dijk MEI, van Miert PPMC, Zhang X, Ten Berge IJM, Claas FHJ. The avidity of cross-reactive virus-specific T cells for their viral and allogeneic epitopes is variable and depends on epitope expression. *Hum Immunol* 2018;79(1):39-50

Culshaw A, Ladell K, Gras S, McLaren JE, Miners KL, Farenc C, **van den Heuvel H**, Gostick E, Dejnirattisai W, Wangteeraprasert A, Duangchinda T, Chotiyarnwong P, Limpitikul W, Vasanawathana S, Malasit P, Dong T, Rossjohn J, Mongkolsapaya J, Price DA, Screaton GR. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8⁺ T cell response. *Nat Immunol*. 2017 Nov;18(11):1228-1237

D'Orsogna L, **van den Heuvel H**, van Kooten C, Heidt S, Claas FHJ. Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. *Immunogenetics*. 2017;69(8-9):631-641

Van den Heuvel H, Heutinck KM, van der Meer-Prins EMW, Yong SL, van Miert PPMC, Anholts JDH, Franke-van Dijk MEI, Zhang XQ, Roelen DL, Ten Berge RJM, Claas FHJ. Allo-HLA cross-reactivities of cytomegalovirus-, influenza-, and varicella zoster virus-specific memory T cells are shared by different healthy individuals. *Am J Transplant* 2017;17(8):2033-2044

Heutinck KM, Yong SL, Tonneijck L, **van den Heuvel H**, van der Weerd NC, van der Pant KA, Bemelman FJ, Claas FH, Ten Berge IJ. Virus-specific CD8⁺ T cells cross-reactive to donor-alloantigen are transiently present in the circulation of kidney transplant recipients infected with CMV and/or EBV. *Am J Transplant*. 2016;16(5):1480-91

Van den Heuvel H, Heutinck KM, van der Meer-Prins EP, Yong SL, Claas FH, Ten Berge IJ. Detection of virus-specific CD8⁺ T cells with cross-reactivity against alloantigens: potency and flaws of present experimental methods. *Transplant Direct* 2015;1(10):e40

Van den Heuvel H, Heidt S, Roelen DL, Claas FH. T-cell alloreactivity and transplantation outcome: a budding role for heterologous immunity? *Curr Opin Organ Transplant* 2015 Aug;20(4):454-60

Turksma AW, Bontkes HJ, **van den Heuvel H**, de Gruijl TD, von Blumberg BM, Braakhuis BJ, Leemans CR, Bloemena E, Meijer CJ, Hooijberg E. Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. *Oral Dis.* 2013 Sep;19(6):577-84

Turksma AW, Bontkes HJ, Ruizendaal JJ, **van den Heuvel H**, Scholten KB, Santegoets SJ, de Gruijl TD, Meijer CJ, Hooijberg E. Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells. *Hum Immunol.* 2013 May;74(5):506-13

D'Orsogna LJ, **van den Heuvel H**, van der Meer-Prins EM, Roelen DL, Doxiadis II, Claas FH. Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules. *J Immunol* 2012;189(10):4825-4831

Abbreviations

ABCD3	ATP-binding cassette sub-family D member 3
Allo-HLA	allogeneic HLA
ATG	anti-thymocyte globulin
CD	cluster of differentiation
CFSE	carboxyfluorescein succinimidyl
CMV	cytomegalovirus
CNI	calcineurin inhibitor
CRA	⁵¹ Chromium-release assay
CTLA-4	cytotoxic T lymphocyte-associated antigen 4
CU	Cetus unit
DLI	donor lymphocyte infusion
EBV	Epstein-Barr virus
EBV LCL	EBV-transformed lymphoblastoid cell line
EFI	European Federation of Immunogenetics
ELISA	enzyme-linked immunosorbent assay
FACS	fluorescence-activated cell sorting
FCS	fetal calf serum
FITC	fluorescein isothiocyanate
FLU	influenza virus
FRET	Förster resonance energy transfer
GVHD	graft-versus-host disease
GVL	graft-versus-leukemia
GVM	graft-versus-myeloma
HLA	human leukocyte antigen
HS	human serum
HSCT	human stem cell transplantation
HUVEC	human umbilical vein endothelial cell
IFN γ	interferon γ
IL-7	interleukin 7
IMDM	Iscove's Modified Dulbecco's Medium
ITAM	immunoreceptor tyrosine-based activation motif
mAb	monoclonal antibody
ME	β -mercaptoethanol
mHAg	minor histocompatibility antigen
MHC	major histocompatibility complex
MLR	mixed lymphocyte reaction
MMF	mycophenolate mofetil
mTOR	mammalian target of rapamycin
NO	nitric oxygen
PBMC	peripheral blood mononuclear cell

PCR	polymerase chain reaction
PE	phycoerythrin
PHA	phytohaemagglutinin
PLT	primed-lymphocyte test
pMHC	peptide-MHC
RPMI	Roswell Park Memorial Institute medium
SOT	solid organ transplantation
SPR	surface plasmon resonance
SSO	sequence-specific oligonucleotide
SSP	sequence-specific primer
TCR	T-cell receptor
TEC	tubular epithelial cell
Th1	type 1 helper T cell
Treg	regulatory T cell
VZV	varicella zoster virus